Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, JungJin, Yang, Eunsol, Jang, In-Jin, Lee, Hyejung, Yoo, Hokyun, Chung, Jae-Yong, Lee, SeungHwan, Oh, Jaeseong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958674/
https://www.ncbi.nlm.nih.gov/pubmed/36839870
http://dx.doi.org/10.3390/pharmaceutics15020549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958674/
https://www.ncbi.nlm.nih.gov/pubmed/36839870
http://dx.doi.org/10.3390/pharmaceutics15020549

Ejemplares similares